⌘K

NEUP

NASDAQ

Neuphoria Therapeutics Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2021

News25/Ratings0

News · 26 weeks280%

2025-10-262026-04-19

Mix190d

SEC Filings1(100%)

Latest news

25 items

65dSEC
SEC Form 10-Q filed by Neuphoria Therapeutics Inc.
10-Q - Neuphoria Therapeutics Inc. (0001191070) (Filer)
92dINSIDER
SEC Form 4 filed by Director Wilson David Ian
4 - Neuphoria Therapeutics Inc. (0001191070) (Issuer)
92dINSIDER
SEC Form 4 filed by Director Davies Peter Miles Winston
4 - Neuphoria Therapeutics Inc. (0001191070) (Issuer)
92dINSIDER
SEC Form 4 filed by Director Fisher Alan
4 - Neuphoria Therapeutics Inc. (0001191070) (Issuer)
92dINSIDER
SEC Form 4 filed by Director Ryan Jane
4 - Neuphoria Therapeutics Inc. (0001191070) (Issuer)
115dSEC
Amendment: SEC Form SCHEDULE 13D/A filed by Neuphoria Therapeutics Inc.
SCHEDULE 13D/A - Neuphoria Therapeutics Inc. (0001191070) (Subject)
126dSEC
Neuphoria Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
8-K - Neuphoria Therapeutics Inc. (0001191070) (Filer)
127dSEC
Neuphoria Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
8-K - Neuphoria Therapeutics Inc. (0001191070) (Filer)
136dSEC
SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.
DEFA14A - Neuphoria Therapeutics Inc. (0001191070) (Filer)
136dPR
Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees
Company Urges Shareholders to Follow ISS' Recommendation and Vote the WHITE Proxy Card BURLINGTON, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ:NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today announced that Institutional Shareholders Services ("ISS"), a leading independent proxy advisory firm, has issued a report recommending that Neuphoria shareholders vote on the WHITE proxy card FOR BOTH of the Company's director nominees – Peter Miles Davies and David Wilson. As previously disclosed, Lynx1 Capital
140dSEC
SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.
DEFA14A - Neuphoria Therapeutics Inc. (0001191070) (Filer)
140dPR
Neuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and Premium
Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest Urges Stockholders to Vote "FOR" BOTH of Neuphoria's Nominees on the WHITE Proxy Card BURLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ:NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statement in response to dissident stockholder, Lynx1 Master Fund LP's ("Lynx1"), revised indication of interest to acquire the Company. Lynx1 Operating Outside Neuphoria's R
143dSEC
SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.
DEFA14A - Neuphoria Therapeutics Inc. (0001191070) (Filer)
143dPR
Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions
BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ:NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statements to address what Neuphoria strongly believes is a campaign from Lynx1 Master Fund LP ("Lynx1") full of deception and distraction to deflect attention from its own limitations and its handpicked nominees' shortcomings. The Company urges stockholders to trust Neuphoria's commitment to transparency and value creation over what it believes are Lynx1's fabrications and misdire
149dSEC
SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.
DEFA14A - Neuphoria Therapeutics Inc. (0001191070) (Filer)
150dSEC
SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.
DEFA14A - Neuphoria Therapeutics Inc. (0001191070) (Filer)
150dSEC
SEC Form DEFC14A filed by Neuphoria Therapeutics Inc.
DEFC14A - Neuphoria Therapeutics Inc. (0001191070) (Subject)
150dPR
Neuphoria Therapeutics Inc. Sends Letter to Stockholders
Files Definitive Proxy Statement for 2025 Annual Meeting of Stockholders Urges Stockholders to Vote "FOR" BOTH Neuphoria Therapeutics Nominees on WHITE Proxy Card BURLINGTON, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company"), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued a letter to its stockholders regarding Neuphoria's 2025 Annual Meeting of Stockholders ("2025 Annual Meeting"), which is scheduled to be held on December 12, 2025. At the 2025 Annual Meeting, Neuphoria stockholders will have the opportunity to pro
160dSEC
SEC Form 424B5 filed by Neuphoria Therapeutics Inc.
424B5 - Neuphoria Therapeutics Inc. (0001191070) (Filer)
160dSEC
SEC Form 10-Q filed by Neuphoria Therapeutics Inc.
10-Q - Neuphoria Therapeutics Inc. (0001191070) (Filer)
162dSEC
SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.
DEFA14A - Neuphoria Therapeutics Inc. (0001191070) (Filer)
162dSEC
SEC Form PREC14A filed by Neuphoria Therapeutics Inc.
PREC14A - Neuphoria Therapeutics Inc. (0001191070) (Subject)
163dPR
Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value
Confirms Receipt of Unsolicited Indication of Interest and Director Nominations from Lynx1 Master Fund LP No Stockholder Action Required at This Time BURLINGTON, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ:NEUP), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced, as previously disclosed, the initiation of a review of strategic alternatives to advance the Company's promising pipeline programs and seek to maximize stockholder value. Strategic alternatives under consideration may include, but are not limited to, mergers, acquisition, partnerships, joint ventur
176dSEC
SEC Form DEF 14A filed by Neuphoria Therapeutics Inc.
DEF 14A - Neuphoria Therapeutics Inc. (0001191070) (Filer)
176dSEC
SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.
DEFA14A - Neuphoria Therapeutics Inc. (0001191070) (Filer)